Shield Therapeutics PLC: Proactive One2One Virtual Event

Shield Therapeutics PLC's (LON:STX) Tim Watts pitches the company to investors at the Proactive One2One Virtual Event. Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Group’s lead product, Feraccru®/Accrufer® has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland.